-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27

Benzinga·10/30/2026 10:41:08
Diffusion vocale
Needham analyst Gil Blum initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $27.